To prepare Europe for an increased threat of coronavirus variants, the President of the European Commission, Ursula von der Leyen, has announced the start of European bio-defense preparedness plan called “HERA Incubator.”
The Health Emergency Preparedness and Response Authority (HERA) Incubator will bring together science, industry and public authorities, and leverage all available resources to enable Europe to respond to this challenge.
“The aim is to use our combined strength to get ahead of the curve for the next phase of this virus”, Ms von der Leyen said, explaining this applies to all phases - from the early detection of new variants, to rapid mass production that is necessary if there are adapted second-level or second-generation vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze